-85+% of Planned Patients Enrolled in MASTER Trial-
-Hosted MGuard Symposium at EuroPCR Last Week-
Report is Available for Download at: www.lifesciadvisors.com/clients/inspiremd
Previously, InspireMD, Inc. (OTC BB: NSPR) issued a press release announcing first quarter financial results for 2012. We report that over 85% of the ongoing MASTER Trial is enrolled with top-line results expected by the third quarter. The Company also strengthened its management team during the quarter and raised ~$11MM in gross proceeds from a private placement completed on April 5, 2012.
?We report that InspireMD hosted a symposium last Thursday, entitled ?Thrombus Management in STEMI: MGUARD? Late Breaking Data,? at the EuroPCR meeting in Paris. This symposium included new results from a 3-year extended follow up of the MAGICAL Trial in 60 STEMI patients and the first European presentation of the MICAMI Trial results.
?MGuard MASTER Trial Reaches ~86% Enrollment and Positive MGuard Data were Presented at the CRT Conference in D.C. InspireMD has made significant progress during the first quarter of 2012. Most notably, the MASTER Trial, which is comparing MGuard to the standard of care stent in STEMI patients, reached ~86% enrollment (370 out of the planned 432 patients). Also during the quarter, the Company presented positive MGuard results from the MICAMI trial at the Cardiovascular Research Technologies (CRT) Conference in Washington D.C. The randomized, controlled trial showed a statistically significant improvement in microvascular reperfusion for MGuard versus bare metal stents, which are the current standard of care.